Business Wire

COLOPL Group Blockchain Game Company Brilliantcrypto, Confirms Partnership with Coincheck Ahead of IEO

20.7.2023 09:00:00 EEST | Business Wire | Press release

Share

Brilliantcrypto, Inc. (HQ: Minato City Tokyo, CEO: Naruatsu Baba, henceforth “Brilliantcrypto”) has partnered with the crypto asset trading service provider Coincheck, Inc. (HQ: Shibuya City Tokyo, CEO: Satoshi Hasuo, henceforth “Coincheck”) ahead of an IEO※1 (Initial Exchange Offering, henceforth “IEO”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719966068/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brilliantcrypto

Brilliantcrypto was established in November 2022 as a wholly owned subsidiary of COLOPL, Inc. (CEO: Takashi Miyamoto, HQ: Minato City Tokyo), to carry out GameFi※2 projects using blockchain technology.

With this partnership, and through the interconnected business of Brilliantcrypto’s currently in-development blockchain game and Coincheck’s crypto asset trading service, the two companies will work together in creating a new game experience and GameFi market on the global stage.

The large-scale Japanese blockchain game project currently in development shall introduce “Proof of Gaming,” a new concept that works for the benefit of others (through guaranteeing value), inspired by the “Proof of Work”※3 mechanism of Bitcoin. Through doing this, it aims to make sustainable play-to-earn※4 a reality.

By utilizing the crypto asset exchange user base and sales network of Coincheck, which is the largest scale exchange and has the best track record with IEOs among domestic crypto exchanges, Brilliantcrypto plans to acquire trust, and aims to achieve a highly enthusiastic user base from the launch period of the game.

Brilliantcrypto will be holding a presentation on July 25th 14:00 JST at the “WebX 2023” event, which will be held at the Tokyo International Forum on July 25th and July 26th. WebX 2023 is a large-scale global conference where the main players in Web3 from countries around the world will gather. On the day, the founder and current chairman of COLOPL, Inc., Mr. Naruatsu Baba will be presenting.

You can view the online livestream by following the link below.
https://www.youtube.com/watch?v=0iEFIMpkf9Q

Comment from Isaka Tomoyuki (Coincheck, Vice-President, Executive Committee Member & Crypto Asset Operations Department Manager)

The GameFi market is still developing, and there is a demand for this new type of game experience that combines finance and entertainment using blockchain technology. Currently, there are many debates taking place about GameFi around the world. But I believe that between theorizing about it, and actually shaping it into something that you can implement into the design of a game that is actually playable, there exists an extraordinarily large gap.

The COLOPL group and its Chief Creator Naruatsu Baba are a rare force in the industry that bridges that gap by delivering original game design aligned with new eras in the gaming industry to their users. I am therefore very pleased to be working on an IEO with the creative team from Brilliantcrypto which is spearheaded by Mr. Baba.

As a leading company for IEOs and crypto asset exchange in Japan, we want to put our full support behind companies that aim to develop the Web3/Crypto industry, or creators that are giving this new type of game design a challenge.

Comment from Naruatsu Baba (CEO of Brilliantcrypto)

Brilliantcrypto was established to take on the challenges of blockchain gaming, and create games that truly shine and stand out. We feel empowered and elated that Coincheck felt a deep connection with our vision “to harness the power of games and blockchain technology to create new value,” and thus decided to become our IEO partner.

Through the partnership of our company, which has spent many years using technology and individualistic ideas to carry out business in the mobile gaming industry, with Coincheck, the largest cryptocurrency exchange in the domestic market, we aim to make a huge impact in not only the Japanese Web3 industry, or even just in the gaming industry, but in all areas of the world.

On July 25th at the WebX 2023 event, which is to be held at the Tokyo International Forum, I plan to deliver a presentation personally and reveal the project to the world. Please look forward to our project, which will bring a never-seen-before, new type of value out into the world.

※1: IEO describes the public offering, sale, and distribution of crypto assets (tokens) that takes place after a project audit/inspection with crypto assets exchange as the medium, following the rules of the Japanese domestic regulation. Until now there have been 4 examples of IEOs performed domestically. Coincheck has carried out two of these including the very first domestic IEO, through the Coincheck IEO platform.

※2: GameFi is a word that combines Game and Finance to describe games that include mechanisms through which one can earn through gameplay, which is made possible by integrating blockchain technology with crypto assets.

※3: Proof of Work (PoW) is one of the consensus algorithms that allows crypto assets to be mined. It allows the transaction and sending of crypto assets, starting with Bitcoin, to be correctly recorded on the blockchain through calculations and verification work. This calculation and verification work is called “mining,” and those who carry it out are called “miners.” PoW is the process in which agreement is reached that the data is correct between the miners through mining.

※4: Play-to-earn is a concept which describes games which make it possible to earn through gameplay, made possible by integrating blockchain technology with crypto assets.

■About Coincheck

Coincheck, Inc. operates a crypto assets exchange platform which for 4 years in a row, has been No.1 in application downloads in that category*. Coincheck’s mission is “Making Exchange of New Values Easier.” Using a foundation of the latest technology and the highest level of security, it aims to create the best service whereby users can feel closer to the “exchange of new values,” which is brought about through crypto assets and blockchain technology.

*Scope: Domestic Crypto Assets Exchange Platforms. Period: 2019/01〜2022/12 Data from App Tweak

Company Name: Coincheck, Inc.
Headquarters: Tokyo, Shibuya City, Maruyamacho, 3-6, 12F E. Space Tower
Founded: 2012/08/28
Executive Director: Satoshi Hasuo
Crypto Asset Exchange Business Registration: Kanto Local Finance Bureau No. 00014
Coincheck, Inc. Corporate Site: https://corporate.coincheck.com/

■About Brilliantcrypto, Inc.

Brilliantcrypto was established in November 2022 as a wholly owned subsidiary by COLOPL, Inc., to carry out GameFi projects using blockchain technology. It was established to take on the challenges of blockchain gaming, and create games that truly shine and stand out. Using both blockchain technology, and the bountiful knowledge gained through the COLOPL group’s many years creating video games, we will create new value on a global scale.

Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba
Brilliantcrypto, Inc. Corporate Site: https://brypto.net

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

<Point of Contact regardings inquiries from the media on this release>
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail: press.contact@brilliantcrypto.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye